Immunocore (NASDAQ:IMCR) Releases Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Immunocore (NASDAQ:IMCR - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.16), Zacks reports. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm had revenue of $105.16 million for the quarter, compared to analyst estimates of $85.86 million.

Immunocore Trading Down 0.7 %

Shares of IMCR stock traded down $0.21 during mid-day trading on Friday, reaching $29.37. The company's stock had a trading volume of 181,954 shares, compared to its average volume of 229,183. The company's 50 day simple moving average is $30.08 and its 200-day simple moving average is $31.81. Immunocore has a 12-month low of $27.69 and a 12-month high of $72.05. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1.47 billion, a PE ratio of -30.92 and a beta of 0.77.

Analyst Upgrades and Downgrades

IMCR has been the topic of a number of analyst reports. Mizuho lowered shares of Immunocore from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $72.00 to $38.00 in a research report on Monday, November 11th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Friday. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday. Finally, Morgan Stanley reiterated an "equal weight" rating and issued a $35.00 price target (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $65.64.

Remove Ads

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.